Increasing prevalence of infectious diseases including pneumonia, tuberculosis, gonorrhea, salmonellosis, and staphylococcal infections are driving the demand for effective anti-infective drugs. Limited pipeline of new antibiotics and increasing investment in R&D are further fueling the market growth.

The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 BN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Antibiotic Resistance Market Growth are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD. These players are actively investing in developing novel antibiotics and combination therapies to treat drug-resistant infections.

The growing prevalence of communicable diseases around the world is driving the demand for effective anti-infective treatments. According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. Failure to treat infectious diseases can jeopardize cancer treatment and major surgery success as well as the care of preterm babies. It can impact anyone, of any age, in any country.

Key players are focusing on expanding their global footprint through acquisitions and collaboration with regional players. Companies are engaged in developing a broad pipeline of antibacterial candidates with novel mechanisms of action to treat serious and life-threatening multi-drug resistant infections lacking adequate treatment options. This is expected to further fuel market growth during the forecast period.

Get more insights on Global Antibiotic Resistance Market